ClinicalTrials.gg

Program

ivarmacitinib

Also written as “SHR0302”, “SHR0302 Tablets” and “SHR0302 Base Gel”.

Its studies are mostly in Arthritis, Rheumatoid · Vitiligo · Alopecia Areata · Colitis, Ulcerative · Dermatitis, Atopic, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Apr 2, 202025 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine254 open or runningphase 3since Apr 2, 2020Apr 7, 2015Mar 2027phase 2 · NCT07251595

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Apr 7, 2015.

  1. Jul 15, 2020Phase 3 study in Spondylitis, AnkylosingNCT04481139 · 504 enrolled · China
  2. Jan 11, 2021Phase 1 study in Healthy SubjectsNCT04712838 · 24 enrolled · China
  3. Feb 24, 2021Phase 3 study in VitiligoNCT04774809 · 75 enrolled · China
  4. May 1, 2021Phase 3 study in Dermatitis, AtopicNCT04875169 · 336 enrolled · Canada, China
  5. Sep 8, 2021Phase 1 study in Arthritis, RheumatoidNCT05047341 · 6 enrolled · China
  6. Dec 10, 2021Phase 3 study in Colitis, UlcerativeNCT05181137 · 368 planned · United States, China, Georgia and more
  7. Apr 6, 2022Phase 3 study in Non-Radiographic Axial SpondyloarthritisNCT05324631 · 300 enrolled · China
  8. May 23, 20222 phase 1 studies in Arthritis, RheumatoidNCT05392127, NCT05404724
  9. Jul 20, 2022Phase 3 study in Alopecia AreataNCT05470413 · 330 enrolled · China
  10. May 4, 2023Phase 1 study in Graft vs Host DiseaseNCT05856058 · 16 enrolled · China
  11. Jan 1, 2024Phase 1 study in Autoimmune DiseasesNCT06202612 · 16 enrolled · China
  12. Jan 20, 2025Phase 2 study in VitiligoNCT06790862 · 155 enrolled · China
  13. Jul 27, 2025Phase 1 study in Preoperative Sedation of AdultsNCT07098117 · 32 enrolled · China
  14. Nov 19, 2025Phase 2 study in Non-segmental VitiligoNCT07251595 · 176 planned · China

Ahead

  1. Mar 2027Primary completion: phase 2 study in Non-segmental VitiligoNCT07251595

TargetBeta

JAK1 →read by rule
“The sulfate salt form of ivarmacitinib, an orally available inhibitor of Janus-associated kinase 1 (JAK1), ”NCIt, by rule

Other programs on JAK1

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
baricitinibruleEli Lillyphase 459
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
abrocitinibrulePfizerphase 330
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
momelotinibruleGlaxoSmithKlinephase 317
golidocitinibruleDizal Pharmaceuticalsphase 310

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07251595Non-segmental Vitiligo · China2RecruitingMar 2027176
NCT07098117Preoperative Sedation of Adults · China1CompletedJul 31, 202432
NCT06790862Vitiligo · China2Active, not recruitingMar 3, 2026155
NCT06202612Autoimmune Diseases · China1CompletedFeb 21, 202416
NCT05856058Graft vs Host Disease · China1CompletedJul 3, 202316
NCT05470413Alopecia Areata · China3Active, not recruitingOct 31, 2023330
NCT05404724Arthritis, Rheumatoid · China1CompletedJul 11, 202214
NCT05392127Arthritis, Rheumatoid · China1CompletedAug 18, 202224
NCT05324631Non-Radiographic Axial Spondyloarthritis · China3UNKNOWNAug 30, 2024300
NCT05181137Colitis, Ulcerative · United States, China, Georgia and more3RecruitingOct 31, 2024368
NCT05047341Arthritis, Rheumatoid · China1CompletedSep 19, 20216
NCT04875169Dermatitis, Atopic · Canada, China3CompletedAug 12, 2022336
NCT04774809Vitiligo · China3TerminatedMar 21, 202275
NCT04712838Healthy Subjects · China1CompletedApr 13, 202124
NCT04481139Spondylitis, Ankylosing · China3CompletedNov 15, 2022504
NCT04333771Arthritis, Rheumatoid · China3CompletedJan 30, 2023566
NCT04293029Hepatic Impairment · China1CompletedDec 27, 202024
NCT04346316Alopecia Areata · United States, Australia, China2CompletedJun 10, 202194
NCT04162899Dermatitis, Atopic · China2CompletedAug 21, 2020105
NCT03677648Crohn Disease · United States, China, Poland and more2CompletedSep 16, 2021112
NCT03675477Colitis, Ulcerative · United States, China, Poland and more2CompletedNov 30, 2020164
NCT03254966Arthritis, Rheumatoid · China2CompletedApr 16, 2019194
NCT02892370Arthritis, Rheumatoid · China1UNKNOWNSep 201614
NCT02665910Arthritis, Rheumatoid · China1UNKNOWNDec 201648
NCT02423538Arthritis, Rheumatoid · China1UNKNOWNJul 201664

How it is read

Names in the registry

  • “SHR0302”, 21 entries
  • “SHR0302 Tablets”, 2 entries
  • “SHR0302 Base Gel”, 2 entries
  • “SHR0302Base gel”, 1 entry
  • “SHR0302 quick release tablets”, 1 entry

Codes read as this program: SHR0302.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.